Author

Mahip Verma

Observed names: Mahip K. Verma, Mahip Kalyan Verma

Institution: Lupin Pharmaceuticals (India)

Observed institution: Lupin Pharmaceuticals (India)

ORCID: 0000-0002-8487-9387

Observed ORCID: 0000-0002-8487-9387

OpenAlex ID: A5107972711

Discovery of Novel, Potent, Brain-Permeable, and Orally Efficacious Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptor [4-(5-(4-Chlorophenyl)-4-methyl-2-propionylthiophen-3-yl)benzenesulfonamide]: Structure–Activity Relationship and Preclinical Characterization

2019 · Neelima Sinha, Navnath P. Karche, et al. · Journal of Medicinal Chemistry · 30

Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure–Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides

2020 · Vidya Ramdas, Rashmi Talwar, et al. · Journal of Medicinal Chemistry · 14

Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models

2020 · Manojkumar R. Shukla, Sukanya Patra, et al. · Journal of Medicinal Chemistry · 13

LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization

2020 · Mahip K. Verma, Rajan N. Goel, et al. · European Journal of Pharmacology · 11

PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways

2023 · Charudatt Samant, Ramesh Kale, et al. · Biochemistry and Biophysics Reports · 8

Inhibition of SGK1 potentiates the anticancer activity of PI3K inhibitor in NSCLC cells through modulation of mTORC1, p‑ERK and β‑catenin signaling

2023 · Ramesh Kale, Charudatt Samant, et al. · Biomedical Reports · 5

Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282

2022 · Mahip K. Verma, Charudatt Samant, et al. · Biochemical and Biophysical Research Communications · 2

Corrigendum to “PAK4 inhibition significantly potentiates gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways” [Biochemistry and Biophysics Reports, (35), September 2023, 1–8 / 101544]

2025 · Charudatt Samant, Ramesh Kale, et al. · Biochemistry and Biophysics Reports

Works count: 8

Citation count: 83

H-index: 5

I10-index: 4